CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 278 enrolled
Drug / intervention
olmesartan medoxomil + hydrochlorothiazide, if necessary +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00430638
NCT00430638Phase 4Completed
CompareCT.gov

A Double-Blind, Randomized, Placebo Controlled, Parallel Group Study to Compare the Safety and Efficacy of an Olmesartan Medoxomil Based Treatment Regimen to Placebo in Patients With Stage I and Stage II Hypertension

Daiichi Sankyo·interventional·Posted Feb 2, 2007·Updated Oct 2, 2018

In Brief

A Phase 4 clinical trial evaluating olmesartan medoxomil + hydrochlorothiazide, if necessary and Placebo for Hypertension. Completed, enrolled 278 participants across 29 sites.

Detailed Summary

This 16 week study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients with moderate to severe high blood pressure in comparison to placebo. The medication being tested has been approved by the FDA for the treatment of high blood pressure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2, 2007
Enrollment StartDec 1, 2006
Primary CompletionOct 1, 2007
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 19.4 years ago

Interventions

olmesartan medoxomil + hydrochlorothiazide, if necessarydrug

olmesartan medoxomil + hydrochlorothiazide, if necessary. Oral tablets administered for once daily for 12 weeks

Placebodrug

Oral tablets administered for once daily for 12 weeks